# Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Study · id `cardio:ct-nct03496883` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03496883](<https://clinicaltrials.gov/study/NCT03496883>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03496883

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 860 participants.

## Technical summary

Registry record NCT03496883. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-03 (actual); primary completion 2028-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 860 participants (planned count; ClinicalTrials.gov record NCT03496883, source copy `cardio:ctgov-nct03496883-2026-01-21`, retrieved 2026-10-31)
- Started: 2021-12-03 (actual) (ClinicalTrials.gov record NCT03496883, source copy `cardio:ctgov-nct03496883-2026-01-21`, retrieved 2026-10-31)
- Primary completion: 2028-01-01 (anticipated) (ClinicalTrials.gov record NCT03496883, source copy `cardio:ctgov-nct03496883-2026-01-21`, retrieved 2026-10-31)
- Completion: 2028-01-01 (anticipated) (ClinicalTrials.gov record NCT03496883, source copy `cardio:ctgov-nct03496883-2026-01-21`, retrieved 2026-10-31)
- Countries: United States; Canada; Germany; Japan; Spain; United Kingdom (ClinicalTrials.gov record NCT03496883, source copy `cardio:ctgov-nct03496883-2026-01-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03496883-2026-01-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
- Acronym: FASTEST
- Condition: Intracerebral Hemorrhage
- Intervention (Biological): Recombinant Activated Factor VII (rFVIIa)
- Intervention (Biological): Placebo
- Lead sponsor: Joseph Broderick, MD
- Lead sponsor class: OTHER
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY
- Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)
- Registry lists this organization as a collaborator: National Institute of Neurological Disorders and Stroke (`cardio:ninds`)

## Provenance

Content hash: 78010e774da590b2f305c9261b9b7efe2903146d4846389c4472038bfe5d59a8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
